Elanco to Acquire Lohmann Animal Health
Elanco acquires Germany-based Lohmann Animal Health.
Elanco, the animal health division of Eli Lilly, reported an agreement to acquire Lohmann SE (Lohmann Animal Health), a privately-held company headquartered in Cuxhaven, Germany. Lohmann Animal Health is a leader in the supply of poultry vaccines and also markets a range of feed additives. The acquisition will establish Elanco as a poultry provider, solidify Elanco's vaccine presence, broaden Elanco's product offerings, and expand Elanco's vaccine manufacturing capabilities, the company says.
Under the terms of the agreement, Lilly will acquire all assets of Lohmann SE and its subsidiary, Lohmann Animal Health. These assets include a range of vaccines and feed additives, commercial capabilities, and manufacturing sites in Cuxhaven, Germany and Winslow, Maine. No other terms of the transaction were disclosed.
The transaction is expected to close in the second quarter of 2014, contingent upon clearance from regulatory authorities and other customary closing conditions.
Source: Elanco
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
